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ABSTRACT
Objectives: To assess the 2009 National Dementia
Strategy’s (NDS) impact on dementia diagnosis and
treatment.
Setting and participants: Primary care data for
England before and after launch of the NDS.
Primary outcome measures: We used nationally
available data to estimate the trends over time in rates
of dementia diagnoses recorded on the Quality
Outcomes Framework (QOF) in Primary Care Trusts
(PCT) and antidementia medication prescriptions from
2006/2007 (the first available figures) and the
associated increase in cost relative to all other
prescriptions. To establish PCT general practitioner
(GP) QOF dementia recording validity, we correlated it
with medication prescription using the NIC (net
ingredient cost).
Results: Regression analysis showed that dementia
diagnosis rate was lower prior to launch of the NDS
and increased significantly after it was launched. The
number of antidementia prescriptions and the cost of
antidementia drugs relative to total PCT prescribing
costs increased significantly after 2009. GP recording
of dementia diagnosis correlated highly with
prescription of cholinesterase inhibitors and
memantine in the same area (p<0.001 each year).
Conclusions: The launch of the NDS was associated
with a significant increase in dementia diagnosis rates
and prescriptions of antidementia drugs. We cannot
establish the causality but this was a change from the
prelaunch pattern. Further assessment of any
intervention to increase the diagnoses should include
an assessment of harm as well as potential benefit.
INTRODUCTION
The number of people with dementia is
rising rapidly worldwide with increased life
expectancy1 2 although the current cohort of
older people may have slightly lower rates of
dementia than their counterparts 20 years
ago.3 Timely diagnosis of dementia can
provide advice, treatment and support which
empowers the person with dementia and
their family, reduces crises and delays institu-
tionalisation.4 It also leads to access to treat-
ments, opportunities to take part in research,
admission to specialist units when physically
ill with a better experience of inpatient care5
and the ability to plan ahead.2 4 6
Nonetheless, diagnosis is often late in the
illness and the majority of people with
dementia are never given a diagnosis,7 even
if they present to their general practitioner
(GP) with symptoms.8 Consequently, early
diagnosis is a key aim of current dementia
policies in the Western world, including
England’s National Dementia Strategy9 but
there is dispute about what strategies to use
to increase the diagnosis rates, partly cen-
tring on the lack of deﬁnitive evidence to
date on the efﬁcacy of interventions to
increase diagnosis6 or the usefulness of
screening.10
Barriers to help-seeking for dementia
include believing that the symptoms are due
to normal ageing, lack of insight of the
person with dementia,11 low levels of knowl-
edge about dementia12 and a lack of conﬁ-
dence among GPs in discussing this
diagnosis.7 13 14 The National Dementia
Strategy (NDS) is the ﬁrst UK government
Strengths and limitations of this study
▪ To our knowledge, this is the first study to
examine the effect of healthcare policy on meas-
urable health outcomes.
▪ Owing to the nature of the intervention being
studied, we could not establish causality.
▪ The mechanisms of change in diagnostic and
prescription rates following the policy launch
remain unclear.
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initiative to focus on improving dementia care through:
raising awareness about the illness; encouraging earlier
diagnosis and intervention (primarily by increased
access to specialist diagnostic services) and increasing
the quality of care that people with dementia receive.9 It
was launched in February 2009 and £150 million of
funding was allocated to Primary Care Trusts (PCTs; who
at that time commissioned health services for their local
areas) to help achieve these objectives. The additional
funding was primarily intended to improve diagnosis
rates and the quality of dementia care, partly through
provision of extra memory clinics. National dementia
awareness campaigns were also launched but no speciﬁc
funding was provided for these.15
The NDS is for England, but similar strategies were
published for Scotland in June 2010 and Wales in
February 2011. Dementia awareness campaigns have
been launched in many countries to improve awareness
of dementia and reduce stigma, in order to improve
detection rates,7 16 but none of these have been evalu-
ated in terms of their impact on measureable outcomes
for people with dementia and their family carers.
Increasing diagnostic rates is theoretically possible
through targeting known barriers. Our recent systematic
review of interventions to increase either the number of
people with diagnoses or timely diagnosis found that
increasing the number of memory services was corre-
lated with higher rates of dementia diagnosis17 and that
they diagnosed people earlier in their illness than trad-
itional old-age psychiatry services.18 In this paper we aim
to explore whether there was an increase in diagnosis
rates after the NDS compared with the preceding period
and whether there was a corresponding increase in the
rate of prescription of antidementia medications (cho-
linesterase inhibitors and memantine).
Objectives
▸ To assess whether the implementation of the NDS
was associated with an increase in the rate of identiﬁ-
cation of people with dementia.
▸ To assess whether the NDS was associated with an
increase in the treatment of dementia with antide-
mentia medications.
▸ In addition, we aimed to consider the validity of
dementia diagnoses on primary care registers.
METHODS
Data description
We established the following ﬁgures in England from
national databases and the Alzheimer’s Society Mapping
the Dementia Gap publications:
▸ Annual national community-level prescribing data
from 2003 to 2012 (calendar year).19
▸ National hospital-level prescribing data from 2007 to
2011 (calendar year).20
▸ Yearly prescribing data of antidementia medications
at Primary Care Trust (PCT; an administrative body
covering local primary care practices) level for 2008/
2009 to 2011/2012 (ﬁscal year—April to March).21
▸ Number of people diagnosed with dementia on
general practitioner (GP) databases by PCT from
2006/2007 to 2011/2012 (these are recorded by GP
practice as quality and outcomes framework (QOF)
data, ﬁscal year).22
▸ Estimated true number of people with dementia in
each PCT from 2010 to 2012.23 24
We divided the number of GP-recorded dementia
diagnoses (from QOF registers) by the estimated total
number of people with dementia. We used the estimates
in the Alzheimer’s Society reports of the actual preva-
lence of dementia in each PCT for 2010–2012. We calcu-
lated the prevalence of dementia for preceding years
using the same method used by the Alzheimer’s Society
in their reports.23 24
As QOF data rely on GPs to enter dementia diagnosis
onto their database, we wished to establish its validity, by
comparison with an independent method of estimating
the rate of dementia diagnosis, that is, with prescription
levels for antidementia drugs calculated by:
▸ Net ingredient cost (NIC): the cost of the drug
before discounts which does not include any dispens-
ing costs or fees.
▸ Items dispensed: a prescription item refers to a single
drug on a prescription so if a prescription form
includes three medicines it is counted as three pre-
scription items.25 The potential disadvantage of
relying on this method of calculating costs is that
regional or temporal differences in prescribing policy
may exist, for example, prescribing for a maximum of
1 month versus prescribing for a maximum of
3 months at a time, which could affect the results
signiﬁcantly.
We used community NIC as hospital NIC data was only
available from 2007, was a relatively small ﬁgure (approxi-
mately 10% of total) and changed over time at around
the same rate. We adjusted the NIC for inﬂation as speci-
ﬁed by the Bank of England inﬂation calculator26 to
enable us to consider whether there were true differences
between years. We correlated the NIC and the number of
items dispensed to check whether they were similar. The
correlation in 2008/2009 between the two was 0.974, in
2009/2010 was 0.968, in 2010/2011 was 0.965 and in
2011/2012 was 0.963 (all p values<0.001), so we con-
cluded that they were very similar. We therefore report
only NIC (as it would theoretically be less prone to vari-
ation over time and between districts) until 2012 when
cholinesterase inhibitors came off-license as follows:
Donepezil, February 2012; Galantamine, January 2012;
Rivastigmine, July 2012.27
We removed Hertfordshire from the dataset in all PCT
level data for prescriptions and diagnoses due to West
Hertfordshire PCT and East and North Hertfordshire
PCT merging into NHS Hertfordshire after 2009/2010.
PCT-level prescribing data rows ‘PCT unidentiﬁed
doctors’ and ‘PCT unidentiﬁed deputising services’ were
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included when calculating totals but removed for com-
parison purposes with QOF data at PCT level. These
data were never more than 0.06% of the total.
Statistical analysis
Numerical data were summarised using mean and SD or
median and range depending on data distribution. We
used Spearman’s rank correlation to assess the mono-
tonic association between two numerical variables.
Dementia diagnosis rates
We used negative binomial regression (NBR) models to
assess the trend in diagnosis rates before and after the
NDS, adjusting for cluster at PCT level. The NBR model
is appropriate for count data and is similar to the
Poisson regression model but is more appropriate in the
presence of over-dispersion.28 The NBR yield estimates
of incidence rate ratio (IRR) and 95% CIs, where an
IRR value of 1 indicates no impact on diagnosis rates.
We used total population at risk as the offset variable in
order to adjust for variable population denominators.
Dementia drug prescriptions
We used NBR to assess the trend in the number of
dementia drug prescriptions, before and after the NDS,
adjusting for cluster at PCT level with the total number
of prescriptions as the offset variable.
We used multilevel linear regression to examine the
effect of NDS on the relative prescription cost, adjusting
for cluster at PCT level.29 We used residual plots to inves-
tigate the assumptions of normality of residuals required
by the multilevel models.
Validity of QOF figures
In order to explore whether areas with a calculated low
diagnosis rate were explained by lack of recording of
dementia diagnoses on the QOF registers, we assessed
the relationship between dementia diagnosis rate and
NIC costs per person diagnosed with dementia. If there
was a bias in reporting then the mean NIC costs per
person diagnosed with dementia would be higher than
in other areas. We categorised diagnosis data and pre-
scription data into quartiles and then assessed the
Spearman’s correlation between them.
All models are ﬁtted with year as a ﬁxed effect.
Descriptive analyses were carried out in SPSS V.20. All
models were ﬁtted in Stata V.12.
RESULTS
Dementia diagnosis numbers and percentages
The number of people with a dementia diagnosis in
England appeared to be similar from 2006 to 2008 but
increased every year after 2008. This is shown in ﬁgure 1.
Dementia diagnosis percentages are available online as a
data supplement.
Dementia diagnosis rates
Table 1 shows the median number of recorded dementia
diagnoses per PCT, the mean proportion of dementia
diagnosed per PCT and change in the mean number
diagnosed per PCT compared with the previous year,
from 2006 to 2012.
Regression analysis showed that dementia diagnosis
rates were lower in 2006–2008 compared with 2009, as
shown in table 2. The dementia diagnosis rate increased
by an estimated 4% in 2010 (IRR 1.04, 95% CI 1.03 to
1.05) and 12% in 2011 (IRR 1.12, 95% CI 1.11 to 1.13)
compared with 2009.
Validity of QOF dementia diagnosis data
Dementia diagnosis rates were highly correlated with the
prescribing data (see table 3). We divided PCTs into
quartiles based on their dementia diagnosis rates and
correlated these with the NIC (see table 4). PCTs in the
quartile with the lowest diagnosis rates had lower correla-
tions with the NIC than those with the higher diagnosis
rates but this was not explained by higher prescribing
costs per person diagnosed.
Antidementia drug prescriptions
The rate of prescriptions of antidementia drugs has
increased dramatically since 2010 (see ﬁgure 2). There
was a down-tick in 2012 in cost (see ﬁgure 3) although
not in the number of prescriptions.
Regression analysis showed that the number of antide-
mentia drug prescriptions increased signiﬁcantly after
2009. The cost of antidementia drugs relative to total
PCT prescriptions costs also increased signiﬁcantly after
2009. All of these results are shown in table 2.
DISCUSSION
Overall, these results indicate that launch of the NDS is
temporally linked to an increase in the diagnosis rates
and in prescriptions of antidementia medications in
England. We found that the mean number of dementia
diagnoses per PCT per year (as reﬂected in GP record-
ing of the diagnosis on their QOF register) and demen-
tia diagnosis rate increased from the year the NDS was
Figure 1 English National diagnosis numbers, 2006/2007 to
2011/2012. *y Axis begins at 200 000 as this was the baseline
for numbers on the quality outcomes framework.
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launched. Prior to this, there was no clear increase in
the number of diagnoses since records began in 2006/
2007; therefore, the change does not seem to be just a
continuation of a trend that was already occurring or
established.
National spending on antidementia medication has
also been increasing over time. There was a signiﬁcant
increase in the mean NIC every consecutive ﬁscal year
since 2008/2009 with the decrease in 2012 probably due
to the lapsing of patents of cholinesterase inhibitors in
England, as prescription numbers continued to increase.
We found a larger increase in items prescribed in 2010,
the year after the NDS was launched and following the
National Institute for Health and Care Excellence
(NICE) guideline amendment in August 2009 to allow
prescription of cholinesterase inhibitors for mild demen-
tia. The costs of antidementia medications as a propor-
tion of overall spending in PCTs also signiﬁcantly
increased following the launch of the NDS.
The mechanism of this change in diagnostic rates and
prescriptions is unclear. The NDS involved provision of
additional funding to PCTs. A government review of how
this was spent found that less than half of PCTs
responded to the survey, of which two-thirds were unable
to say where they had allocated the money. Those who
could comment on spending mostly prioritised funding
memory services and early diagnosis.30 It is unlikely that
those who were unable to say where it was spent used it
for dementia and thus it appears that most of the
funding was not used for the intended purpose.
Therefore, increased spending seems unlikely to be the
sole mechanism of change. It is, however, clearly essential
to fund services in line with growing demand and ideally
this funding should be ringfenced.31
The other two elements of the NDS were national
dementia awareness campaigns and addressing the
quality of dementia care partly through the establish-
ment of memory clinics. A memory clinic survey with an
80% response rate found that the number of people
using memory services in each PCT was 1.5 times higher
in 2010/2011 than in 2008/2009.32 In England, consist-
ent with the NICE guidelines, most of the GPs do not
diagnose dementia and initiate medication. An increase
in diagnosis rates therefore indicates an increase in spe-
cialists’ diagnoses, probably in memory clinics as they
are now the assessment and diagnosis route in most ser-
vices for people with suspected dementia. This accords
with previous reports of an increase in numbers diag-
nosed with dementia with the establishment of memory
clinics.17 33 Nationally and internationally, relabelling
mental health services as ‘memory clinics’ may also
reduce the barrier to diagnosis caused by the stigma of
attending mental health services.34
It may also be that GPs’ and the public’s opinion
about obtaining a dementia diagnosis has changed with
the national awareness campaigns, meaning GPs are
more willing to suggest the possibility of the diagnosis
and refer patients who are more willing to have further
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assessment, but we were unable to ﬁnd evidence about
opinion stability or change.
Strengths and limitations
To our knowledge, this is the ﬁrst study to test the effect
of government policy on measureable outcomes in
dementia. This is an area that deserves further study to
ensure the best use of resources in managing dementia
and other illnesses.
The QOF provides a ﬁnancial incentive for GP prac-
tices to create and maintain a register of patients with
dementia. It is a voluntary reward scheme and there has
been some debate about whether it provides an accurate
estimate of numbers diagnosed with dementia. We
tested its validity and found the QOF data to be highly
correlated with prescriptions for antidementia medica-
tion, indicating that it is a valid measure of the number
of people diagnosed with dementia. There is still a
Table 3 Spearman’s rank correlation between numbers of people with dementia diagnoses on PCT quality outcome
framework register with PCT level prescription data
Years
Correlation of dementia diagnosis
against items dispensed p Value
Correlation of dementia
diagnosis against NIC p Value
2008/2009 0.58 <0.001 0.61 <0.001
2009/2010 0.57 <0.001 0.61 <0.001
2010/2011 0.57 <0.001 0.62 <0.001
2011/2012 0.56 <0.001 0.61 <0.001
NIC, net ingredient cost; PCT, primary care trust.
Table 4 Spearman’s rank correlation between dementia diagnosis rates divided into quartiles and prescription costs
Years
Quartile (lowest
to highest
diagnosis rates)
Number of
PCTs* in
each group
Mean NIC (SD)
per person on
dementia register
Correlation
between NIC and
diagnosis rate p Value
2009–2010 1st 37 303.4 (177.3) 0.533 0.001
2nd 38 357.0 (131.5) 0.571 <0.001
3rd 38 317.0 (166.5) 0.655 <0.001
4th 37 333.8 (136.2) 0.684 <0.001
2010–2011 1st 37 329.5 (163.6) 0.497 0.002
2nd 38 328.9 (176.5) 0.604 <0.001
3rd 38 302.0 (164.6) 0.644 <0.001
4th 37 358.5 (127.1) 0.764 <0.001
2011–2012 1st 37 331.4 (185.8) 0.384 0.019
2nd 38 360.4 (167.4) 0.742 <0.001
3rd 38 337.3 (177.3) 0.548 <0.001
4th 37 379.3 (136.4) 0.717 <0.001
*NIC, net ingredient cost; PCT, primary care trust.
Table 2 Results of regression analyses for dementia diagnosis and antidementia drug prescriptions
Years
Dementia diagnosis
Numbers of antidementia drug
prescriptions
Cost of antidementia drugs
compared with overall spending
Estimate* (95% CI)
p Value
Estimate† (95% CI)
p Value
Estimate‡ (95% CI)
p Value
<0.001 <0.001 <0.001
2006 0.96 (0.53 to 0.97) No data available No data available
2007 0.98 (0.97 to 0.98) No data available No data available
2008 0.94 (0.93 to 0.95) 0.88 (0.84 to 0.92) −0.95 (−1.13 to −0.68)
2009 Reference year
2010 1.04 (1.03 to 1.05) 1.11 (1.06 to 1.16) 0.54 (0.27 to 0.81)
2011 1.12 (1.11 to 1.13) 1.24 (1.19 to 1.29) 2.26 (1.99 to 2.53)
*Estimates represent incidence rate ratio of dementia diagnosis relative to year 2009 obtained from negative binomial regression, offset
against population at risk.
†Estimates represent incidence rate ratio of number of antidementia drug prescriptions relative to year 2009 obtained from negative binomial
regression, offset against total number of prescriptions.
‡Estimates represent the mean difference in relative cost of dementia drug obtained by multilevel linear regression compared with 2009.
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signiﬁcant amount of variance in prescription which is
unexplained by diagnosis rate. However, areas which
had low diagnosis rates did not have higher prescription
rates per person diagnosed with dementia, indicating
that there is not a systematic omission of people with
dementia from the QOF register in these areas.
Although antidementia drugs are recommended in the
UK across all the dementia severity ranges and there is
no reason to think that the proportion of people with
Alzheimer’s dementia varies across areas, we do not
know whether some practitioners prescribe in different
ways. However, our analysis ﬁnds no systematic pattern in
the PCTs with low dementia diagnosis percentages and
therefore suggests that the low rates are not accounted
for only by a failure to record diagnosis.
Owing to the nature of the intervention being studied,
we could only establish associations and temporal links
between the launch of the NDS and outcomes. It may
be that there is another explanation for the changes,
including a change in peoples’ perceptions about
dementia. This could account for the launch of the
NDS and the change in diagnosis and prescription rates.
Also, the NDS is a policy change with a wide remit and
regional variation in its application. It is therefore difﬁ-
cult to say with any certainty which aspect of the NDS
may account for the changes in outcomes we have seen.
Finally, all our data were retrospective and not speciﬁc-
ally collected with the aim of assessing the impact of the
NDS, therefore systematic error cannot be ruled out.
Although we did not have any data on the timeliness
of the dementia diagnoses being made, if the increase
in dementia diagnosis is due to more diagnoses being
made in memory services, these diagnoses are likely to
be more timely.18
Policy and research implications
More than half of people with dementia are still not
diagnosed and others are diagnosed late in the illness
and therefore do not have the beneﬁts of timely diagno-
sis described above. If more diagnoses for dementia are
made in a timely manner, this should improve individual
experience of the illness and have positive implications
for health and social care costs. Further effective inter-
ventions to increase the number of timely dementia
diagnoses are still needed and these interventions
should consider harm in terms of anxiety increase in
the ‘worried well’ as well as beneﬁt and cost. As more
antidementia drugs come off-license in the UK, costs
associated with earlier diagnosis of dementia could fall
despite an increase in the number of prescriptions,
which could be an important factor in assessing the
costs and beneﬁts of future interventions.
Our results suggest that government policy has a sig-
niﬁcant effect on the number of people diagnosed with
dementia and prescription of antidementia drugs but
this is unlikely to be due only to additional funding. In
particular, more people have accessed the rebadged
memory services than mental health services and it may
be important to consider the publics’ perception of ser-
vices as well as their funding and operation.
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